Protagonist Therapeutics, Inc.

How big is Protagonist Therapeutics, Inc.?

As of Jun 18, Protagonist Therapeutics, Inc. has a market capitalization of $3.42 billion, with net sales of $207.80 million and a net profit of $56.19 million over the last four quarters. As of Dec 24, shareholder's funds are $675.29 million, and total assets are $746.83 million.

As of Jun 18, Protagonist Therapeutics, Inc. has a market capitalization of 3,422.02 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 207.80 million, while the sum of net profit for the same period is 56.19 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 675.29 million, and total assets amount to 746.83 million.

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies for unmet medical needs. As of March 2025, it reported net sales of $28 million and a net loss of $12 million, with a market cap of approximately $3.42 billion.

Overview: <BR>Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the Pharmaceuticals & Biotechnology industry, focused on discovering and developing new chemical entities to address significant unmet medical needs.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,422.02 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 60.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.83 <BR>Return on Equity: 8.16% <BR>Price to Book: 4.97 <BR><BR>Contact Details: <BR>Address: 7707 Gateway Blvd Ste 140, NEWARK CA: 94560-1160 <BR>Tel: ['1 510 4740170', '1 646 3782923'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.protagonist-inc.com/

Should I buy, sell or hold Protagonist Therapeutics, Inc.?

Who are in the management team of Protagonist Therapeutics, Inc.?

As of March 2022, the management team of Protagonist Therapeutics, Inc. includes Dr. Harold Selick (Independent Chairman), Dr. Dinesh Patel (President and CEO), and several Independent Directors: Mr. Bryan Giraudo, Dr. Sarah Noonberg, Ms. Sarah O'Dowd, Mr. William Waddill, and Dr. Lewis Williams. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Protagonist Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Harold Selick, who serves as the Independent Chairman of the Board.<BR>- Dr. Dinesh Patel, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Bryan Giraudo, an Independent Director.<BR>- Dr. Sarah Noonberg, an Independent Director.<BR>- Ms. Sarah O'Dowd, an Independent Director.<BR>- Mr. William Waddill, an Independent Director.<BR>- Dr. Lewis Williams, an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is Protagonist Therapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, Protagonist Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 3 October 2025, the technical trend for Protagonist Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish. The daily moving averages indicate a bullish stance. However, the monthly RSI shows a bearish signal, and the KST is mildly bearish on a monthly basis. Bollinger Bands are mildly bullish on both weekly and monthly time frames. Dow Theory and OBV show no trend in either time frame.<BR><BR>In terms of performance, Protagonist Therapeutics has outperformed the S&P 500 year-to-date with a return of 66.17% compared to 14.18%, and over the past year with a return of 44.56% versus 17.82%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Is Protagonist Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Protagonist Therapeutics, Inc. is considered very expensive and overvalued due to high valuation ratios, including a P/E of 60 and an EV to EBITDA of 94.50, especially when compared to peers like Aurinia Pharmaceuticals, which has a P/E of 20.87.

As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. moved from expensive to very expensive. The company appears to be overvalued based on its high valuation ratios, including a P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89. In comparison, Aurinia Pharmaceuticals, Inc. has a more reasonable P/E ratio of 20.87 and an EV to EBITDA of 12.92, indicating that Protagonist is trading at a significant premium relative to its peers.<BR><BR>Despite a strong year-to-date return of 100.78% compared to the S&P 500's 13.30%, the high valuation metrics suggest that the stock may not be sustainable at its current levels. The substantial disparity in valuation ratios, particularly when compared to its peers, reinforces the conclusion that Protagonist Therapeutics is overvalued.